Biotech entity
All 1 tracked stories fall under one category: fda-approval. Of the tracked stories, 1 of 1 also mention Jun Takahashi, the most common co-covered peer. Shinya Yamanaka appears in 1 tracked Biotech story from March 6, 2026. The tracked stories average 3 original sources each.
Last mentioned: Mar 6, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: fda-approval. Of the tracked stories, 1 of 1 also mention Jun Takahashi, the most common co-covered peer. Shinya Yamanaka appears in 1 tracked Biotech story from March 6, 2026. The tracked stories average 3 original sources each.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 18 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Shinya Yamanaka. Shared-story counts are live from our verified record — not editorial picks.
Regulatory Approval
Japan grants official approval for commercial use of the therapy.
Trial Completion
Phase II data confirms safety and efficacy in human subjects.
First Human Trial
Kyoto University begins the world's first iPS cell transplant for Parkinson's.
Nobel Prize
Yamanaka wins the Nobel Prize in Medicine for his iPS cell research.
iPS Discovery
Shinya Yamanaka discovers how to create induced pluripotent stem cells.
Japan has officially approved the world's first stem-cell-based treatment for Parkinson's disease, utilizing induced pluripotent stem (iPS) cells. The therapy, developed by Kyoto University and Sumitomo Pharma, marks a historic shift from symptom management to regenerative repair for neurodegenerative disorders.
Shinya Yamanaka is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
